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Abstract
The Effects of Interleukin-1β on Cardiac Reserve and Exercise Capacity in the Mouse
By Habeebah Z. Vohra, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2021
Major Director: Stefano Toldo, Ph.D., Department of Internal Medicine
Background: Heart failure (HF) is characterized by dyspnea, fatigue, and exercise intolerance.
Clinical evidence points to increased interleukin-1β (IL-1β) activity in patients with HF, with an
IL-1 blockade improving the exercise capacity in HF patients. In healthy mice, recombinantmouse IL-1β (rmIL-1β) induces acute systolic dysfunction, peaking 4 hours after administration.
However, the direct effects of rmIL-1β on exercise capacity are unknown.
Hypothesis: rmIL-1β diminishes the exercise capacity in the mouse.
Methods: Adult mice were trained to run on a treadmill and exercise capacity was assessed
before, 4 hours, and 96 hours after intraperitoneal administration of rmIL-1β (3 μg/kg) or vehicle
(0.9% NaCl) (N=7-10/group). In separate groups of mice, left ventricular ejection fraction
(LVEF) was assessed before, 4 hours, and 96 hours after intraperitoneal administration of rmIL1β (3 μg/kg) or vehicle (0.9% NaCl) using transthoracic echocardiography. The ultrasound
operator was blinded to treatments. The cardiac reserve was measured by calculating the
difference in LVEF before and after β-adrenergic stimulation using isoproterenol (10 ng/mouse)
in IL-1β and vehicle-treated mice (N=5-11/group).
Results: Treatment with rmIL-1β significantly reduced exercise capacity measured at 4 hours
and 96 hours (32% and 33% reduction, respectively, P<0.01 vs baseline), whereas no effect was
observed in the vehicle-treated group (P<0.05 vs IL-1b-treated group). LVEF was significantly
v

reduced 4 hours after treatment with rmIL-1b (29% reduction, P<0.01 vs baseline), without any
significant changes after treatment with vehicle. After 96 hours, LVEF had recovered to pretreatment values. Cardiac reserve was significantly reduced 4 hours and 96 hours after IL-1β
administration (7% and 2% LVEF change, respectively, P<0.05 vs baseline) but not after vehicle
administration (P<0.05 vs IL-1b-treated group).
Conclusion: Administration of exogenous IL-1β reduces exercise capacity through an
impairment in cardiac reserve.

vi

Introduction
Heart Failure
The prevalence of heart failure (HF) is increasing overtime along with the aging of the
population. An estimated 6.2 million Americans over the age of 20 years had HF between 2013
and 2016 which was an increase from an estimated 5.7 million between 2009 and 2012.
Approximately half of hospitalized HF events are characterized by reduced left ventricular
ejection fraction (LVEF) and the other half by preserved ejection fraction.1 For patients under the
age of 65, the most common type of HF is with a reduced ejection fraction (HFrEF)2 and for
patients over the age of 70, the most common type of HF is with a preserved ejection fraction
(HFpEF).3 While contemporary HF treatments have slowed disease progression and improved
survival, the overall incidences of HF morbidity and mortality continue to rise.4,5
HF is a complex clinical syndrome that can result from any structural or functional
cardiac disorder that impairs the ability of the ventricle to fill with or eject blood.6 It is the
inability to provide sufficient blood flow to meet the needs of the body for oxygenation during
regular activity or to do so only with elevated pressures in the heart.7 HF is characterized by
dyspnea, fatigue, and peripheral fluid retention which alone or in combination may limit a
person’s ability to perform activities.4,5 It represents the final phenotype for a variety of
cardiovascular diseases culminating in impaired cardiac systolic and/or diastolic function.8
As cardiac output decreases due to stresses placed on the myocardium, activation of the
sympathetic nervous and renin-angiotensin-aldosterone systems increases blood pressure and
volume. The activation of these compensatory mechanisms can lead to further myocardial
deterioration and worsening contractility. In HFrEF, cardiac output is decreased directly through
a reduced LVEF and is characterized by systolic dysfunction. HFpEF is characterized by
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diastolic dysfunction in which cardiac output is compromised by poor ventricular compliance,
impaired relaxation, and high end-diastolic pressure.6,9

Risk Factors for HF
Coronary artery disease (CAD) is the most common underlying etiology in patients with
HFrEF10,11 and a predictor for the progression from asymptomatic to symptomatic left ventricular
systolic dysfunction. Hypertension and valvular heart disease are significant risk factors for HF
as well.11 Cardiomyopathy is a disease that causes the heart to ineffectively pump blood which
can lead to HF. The main types are dilated, hypertrophic, restrictive, and diabetic
cardiomyopathy. Dilated cardiomyopathy is the enlargement of the left ventricular cavity while
hypertrophic cardiomyopathy involves abnormal thickening of the left ventricular myocardium
and restrictive cardiomyopathy is the stiffening of the myocardium without an increase of
cardiac mass.12 Diabetes mellitus increases the risk of HF twofold by directly leading to
cardiomyopathy and significantly contributing to CAD, and is the strongest risk factor for HF in
women with CAD.13 Common to CAD, hypertension, valvular heart disease, and
cardiomyopathies is an elevation of proteins involved in inflammatory processes14–17 which
continue to be present in HF.
All cardiomyopathies are associated with a compensatory activation of the sympathetic
nervous system (SNS), the renin–angiotensin–aldosterone system (RAAS), and natriuretic
peptides. Activation of these pathways is referred to as “neurohormonal activation”, which acts
to restore and improve the function of the cardiovascular system and prevent a decrease in the
cardiac output. However, overtime, a sustained neurohormonal activation drives the progression
of HF through the deleterious effects exerted on the circulation and the myocardium. Classes of
medications commonly prescribed to patients with HF target these pathways or aim to reduce the
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energy consumption in cardiomyocytes. These include angiotensin-converting enzyme (ACE)
inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors
(ARNI), aldosterone antagonists, diuretics, β-adrenergic blocking agents, If channel blockers,
digoxin, the nitric oxide donor hydralazine and isosorbide dinitrate (specifically benefiting
African Americans with HF).18 These pharmaceutical strategies developed over the course of the
past decades have been successful in reducing mortality from HF, yet the burden of disease
remains unacceptably high.8,19,20 This phenomenon highlights the need to identify new
pathophysiological pathways that participate in HF development and progression.

HF and Functional Capacity
Patients diagnosed with HF, regardless of the cause, demonstrate a compromised
functional capacity. Functional capacity describes a person’s ability to perform daily activities
that require physical exertion. The ability to perform aerobic activities is a central, but not
complete, determinant of functional capacity. It is well established that HF patients demonstrate
attenuated muscular strength and endurance because of the progression of their disease.
Typically, their ability to perform daily activities that are either aerobic or resistive in nature is
compromised and contribute to the decline in functional capacity.21
One of the hallmarks of HF is exercise intolerance which is accompanied by symptoms of
fatigue and shortness of breath.22,23 As the disease progresses, patients experience a downward
spiral as these symptoms usually result in reduced physical activity leading to progressively
worse exercise intolerance.24,25 Typically, patients with HF are faced with what is termed
functional disability26–28 which is their inability to carry out daily activities leading them to suffer
from an impaired quality of life.29–31
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Inflammation and HF
The immune system works to restore tissue homeostasis through an integrated response
that involves inflammation. The activation of inflammation within the heart is tightly regulated
and can either be beneficial or lead to harm.32 Inflammation is an important process activated
following the perturbation of cellular or organ homeostasis. It can modify the cellular or organ
function and as a physiological response, it coordinates the return to homeostasis. There are two
different types of inflammation based on the triggers of immune response: inflammatory
response initiated by exogenous or endogenous (also called sterile) inducers.32
Pathogen-associated molecular patterns (PAMPs) activate the innate immune system
involving monocytes-macrophages, dendritic cells, and natural killer cells that interact with each
other through a wide variety of cytokines including type I and type II interferons, which in turn
have potent anti-viral effects.33 Persistent viral antigens elicit the adaptive immune system with
clonal expression of antigen-specific T and B lymphocytes, ensuing cellular and antibodymediated immune responses, respectively. Although innate and adaptive actions are fundamental
to resolve cardiac infection, when unopposed, they elicit cardiac injury, cardiomyocyte death,
and, eventually, loss of myocardial contractility.32 Myocarditis is the prototype of cardiac
inflammation initiated by exogenous sources and is most often second to viral infection.34 Often
self-limiting, it can debut with or progress to HFrEF.
Endogenous inducers of inflammation have been called danger-associated molecular
patterns (DAMPs).33 Similar to PAMPs, DAMPs activate the innate immune response and can
modify the activity of T and B lymphocytes during the course of heart disease development.
In the cardiovascular system, inflammation is a central pathway that is often linked to the
pathogenesis of cardiovascular disease. The infiltration of leukocytes, cytokine production, and
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phagocytic removal of cellular debris are essential for cardiac repair after myocardial
infarction.35 The persistence of cardiac inflammatory signals, however, is implicated in
maladaptive cardiac remodeling that can lead to HF following ischemic or non-ischemic injury.
Inflammation has long been known to be associated with HF and to predict the outcome of
affected patients. In recent years it is increasingly recognized as one of the factors promoting HF
initiation and progression. Patients with HF have elevated levels of pro-inflammatory markers,
and animal models show a causative role of inflammation in the pathophysiology of CVD and
HF.32,36
After myocardial infarction, cell, tissue, plasma, and extracellular matrix-derived
products trigger an immune response like the one induced by infections, including the
recruitment of leukocytes and secretion of cytokines.32 Moreover, increased production of
cytokines such as interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) by cardiac
fibroblasts has been associated with reduction in collagen synthesis and expansion of the
infarcted area.35 (Fig. 1) Elevated local and systemic inflammatory markers correlate with the
deterioration of cardiac function and predict worse outcomes in both HFrEF and HFpEF.37–39
Paradoxically, sustained inflammation within the myocardium causes extracellular matrix
degradation via matrix metalloproteinases (MMPs) promoting a maladaptive ventricular
remodeling that promotes the development of HF.40
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Figure 1: Inflammatory pathways in HFrEF 32

Inflammation also favors the decrease in sarcoplasmic reticulum (SR) calcium load in
cardiomyocytes, which characterizes HFrEF.41 Two mechanisms are, at least in part, responsible
for this phenomenon: decreased expression and activity of the SR calcium ATPase (SERCA),
which is responsible for ~70% of cytosolic calcium reuptake in humans,42 and increased diastolic
calcium leakage from the SR via ryanodine receptors (RyRs).41 Because of the reduced SR
calcium availability, systolic contraction is impaired; on the other hand, calcium accumulation in
diastole slows myocardial relaxation and enhances cardiomyocyte tension. In addition, the
elevated calcium in diastole increases the open probability of the RyRs, causing spontaneous SR
calcium release, which is a predisposition to early afterdepolarizations triggering ventricular
arrhythmias.43 Pro-inflammatory cytokines, such as IL-1β, IL-6, IL-18 and TNF-α, affect
SERCA function.38,44
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Conversely, HFpEF is thought to be caused by systemic inflammation resulting in injury
of cardiac cells, in a way that identifies this type of HF as an “inflammatory” disease, similarly
to what has been observed in atherosclerosis.32 The current paradigm of HFpEF pathophysiology
recognizes comorbidity-initiated subtle, chronic, systemic inflammation the origin of cardiac
alterations. (Fig. 2)

Figure 2: Inflammatory pathways in HFpEF32

According to this model, coronary microvascular inflammation and dysfunction lead to
cardiomyocyte hypertrophy, stiffness, and myocardial fibrosis.45 Comorbidities accompanying
HFpEF, such as, in particular, metabolic syndrome and diabetes, are associated with low-grade
chronic inflammation.46–48 HFpEF patients have increased circulating markers of inflammation.49
It has been postulated that the primary cardiac alterations in HFpEF are coronary microvascular
endothelial dysfunction, oxidative stress, and inflammation. (Fig. 2) Local release of cytokines,
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including transforming growth factor-β (TGF-β), stimulate the differentiation of fibroblasts into
myofibroblasts, which secrete collagen, in turn, making the ECM stiffer.45,50

Interleukin-1β Production and Signaling
The IL-1 family has 11 cytokines and 10 receptors; two related genes code for the
isoforms IL-1α and IL-1β that are part of this family. IL-1α is synthesized as a fully active
peptide that remains membrane-bound or may be released from the cytoplasm during cell death.
IL-1α thereby participates more prominently in the local response to injury and less in the
systemic inflammatory response.51,52 IL-1β, the main form of circulating IL-1, is initially
synthesized as a precursor (proIL-1β) that becomes activated by caspase-1 cleavage in the setting
of a macromolecular structure known as the inflammasome, a multiprotein complex that
contributes to the recognition of harmful intracellular substances.51,53 Sterile cellular debris
activate sensing pathways33 and elicit the assembly of inflammasomes. Among the five different
types of inflammasomes, the nucleotide oligomerization domain (NOD)-like receptor pyrin
domain-containing 3 (NLRP3) inflammasome has been identified in the myocardium as a
potential player in maladaptive post-ischemic cardiac remodeling.54 The scaffolding proteins
ASC and procaspase-1 are the core inflammasomes. In response to stimulation, the assembly of
the complex of NLRP3, ASC, and procaspase-1 autoactivates caspase-1, which is then
responsible for the activation of pro-inflammatory cytokines such as IL-1β or IL-18.32 IL-1α is
an inflammasome-independent cytokine that binds to the same receptor as IL-1β, the IL-1
receptor type 1 (IL-1R1). However, the inflammasome formation can promote the release of IL1α from the cytoplasm.55 Caspase-1 also participates in the secretion of active IL-1β that can
partake in autocrine, paracrine, and endocrine signaling.51,52 Both IL-1 isoforms induce proIL-1β
synthesis, as do other proinflammatory stimuli like numerous Toll-like receptor agonists.51,56
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Many other potential triggers of the inflammasome have been identified, including microbial
antigens, cell debris, ATP, ischemia, cholesterol crystals, and other Toll-like receptor ligands
such as DAMPs or PAMPs.53,57–60 Activation of the inflammasome after tissue injury induces a
local surge of IL-1β that significantly amplifies the inflammatory response, recruiting more
inflammatory cells, stimulating metalloproteinase activities, and ultimately inducing
inflammatory cell death (pyroptosis) in leukocytes and resident cells.61–63
IL-1 mediated inflammation is initiated when IL-1 binds its two receptors, IL-1R1, the
ligand binding chain, and the IL-1 receptor accessory protein (IL-Rap or IL-1R3), the coreceptor.
Both IL-1α and IL-1β bind to IL-1R1 to cause a structural change that allows IL-1R3 to bind and
form a heterotrimeric complex. The intracellular domains of each of the two receptors contain
the Toll-IL-1-receptor (TIR), which is found in all members of the IL-1 family of receptors.
Because this domain is nearly identical to the TIR domain of TLRs (Toll-like receptors)
associated with microbial pathogens, the IL-1 family and the TLR family share the same
proinflammatory mechanisms for inducing inflammation. When the two intracellular complexes
come together, the adaptor protein, MyD88 (myeloid differentiation factor 88) binds to the TIR
domain. The binding of MyD88 leads to a rapid cascade of phosphorylation resulting in the
activation of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells).55
Interleukin-1 and Inflammation
There is a significant correlation between declining functional class and increasing levels
of inflammatory cytokines in HF patients.37 Clinical evidence points to increased IL-1β activity
in patients with HF, with IL-1 blockade improving the exercise capacity in HF patients. IL-1 is
an apical proinflammatory mediator in acute and chronic inflammation and an inducer of the
innate immune response.51,52 Its production and activity are finely regulated as very small levels
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of exogenous IL-1 can induce sepsis-like syndrome and shock.51,52 IL-1 induces synthesis of
many secondary inflammatory mediators as well as inducing its own production and processing,
which is a key process in the pathogenesis of many autoinflammatory diseases.51,52,64
IL–1β is a prototypal inflammatory cytokine that causes an acute phase reaction
following tissue injury and is persistently elevated in patients with chronic HF.65–67 In early
investigations of septic cardiomyopathy, IL-1β was identified as a soluble “depressant factor” in
the sera, producing a concentration-dependent depression of myocyte contractility in vitro.67
Further studies identify a pathologic role for IL-1β in ventricular remodeling, systolic
dysfunction, and cardiomyocyte death in both ischemic and non-ischemic models of HF.67–72 IL1β has also been shown to affect β-adrenergic receptor sensitivity in vitro, which may be a key
determinant of exercise tolerance in HF patients.73,74 IL-1β contributes to the pathogenesis of HF
by inducing both systolic and diastolic dysfunction. (Fig. 3)

Figure 3: IL-1 signaling in HF36
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Systolic function is impaired through the uncoupling of both L-type calcium channels and
adenylyl cyclase to β-adrenergic receptors, resulting in desensitization to endogenous or
exogenous β-adrenergic agonists. Diastolic dysfunction occurs due to impaired calcium reuptake
by the SR through down-regulation of phospholamban and SERCA.36
Although IL-1β is identified in HF, the direct effects of IL-1β on exercise capacity are
unknown. In healthy mice, administration of recombinant-mouse IL-1β (rmIL-1β) induces acute
systolic dysfunction, peaking 4 hours after administration. Continuous injections of rmIL-1β for
15 days produce a continuous dysfunction that resolves within 5 days. (Fig. 4)

Figure 4: Effects of recombinant IL-1β on left ventricular function in the mouse. IL-1β induces a reversible reduction in left
ventricular function that was maintained throughout chronic dosing at day 15. By day 20, 5 days after stopping IL-1β, LVFS had
returned to values close to baseline.75

The effects of IL-1β and IL-18 on contractility are transient and reversible,75 supporting the
hypothesis that blocking these cytokines could improve or restore cardiac function in humans.
The link between IL-1β and HF is also supported by elevated circulating levels of IL-1β as well
as surrogate biomarkers such as IL-1Ra (IL-1 receptor antagonist), IL-6, or CRP, each of which
correlates with worsening HF symptoms and outcomes.37,76–79
The definitive data from the CANTOS (Canakinumab Anti-inflammatory Thrombosis
Outcomes Study)80 established that IL-1β blockade with canakinumab, an IL-1β antibody, in
11

patients with stable atherosclerotic CVD prevents recurrent cardiovascular events and, thus,
provides compelling proof for the IL-1β atherothrombosis concept.81 The benefit of canakinumab
on clinical events was independent of any effect on lipoproteins or blood pressure, and it was
closely related with the inflammatory response, as patients showing the greatest reduction in Creactive protein (CRP) had improved survival with canakinumab.82 This preclinical data shows
that IL-1 and the NLRP3 inflammasome are involved in the formation and progression of the
atherosclerotic plaques, and IL-1β blockade with canakinumab reduces cardiovascular events in
patients with previous coronary atherothrombotic events.55
In a study of 23 patients with rheumatoid arthritis—a condition with elevated IL-1β
levels—a single dose of 150 mg of anakinra, a recombinant IL-1Ra, resulted in a significant
improvement in cardiac and vascular function.83 In another study, anakinra administered to
patients with stable chronic systolic HF resulted in a significant reduction in circulating levels of
CRP and IL-6 levels; these patients experienced a significant improvement in cardiorespiratory
function (measured as peak oxygen consumption) and quality of life related to cardiac fitness.84
In a study with patients hospitalized for acute decompensated systolic HF, anakinra initiated
within 24 hours of admission had significantly reduced acute inflammatory responses compared
with placebo and after 14 days of treatment, LVEF had improved.85 In another study with
patients hospitalized for acute decompensated systolic HF, anakinra was initiated at discharge
and continued for 12 weeks which resulted in improved cardiorespiratory function, reduced
levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide), and increased quality of life.86
A study with 31 HFpEF patients showed significant increases in treadmill exercise time, lower
NT-proBNP levels, and improved quality of life measures without significant change in peak
oxygen consumption.87 This preclinical data shows that the IL-1 contributes to cardiac
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dysfunction, and IL-1 blockade with anakinra or canakinumab in patients with HF improves
cardiorespiratory fitness and prevents HF hospitalizations.55

Contractile Reserve
Myocardial contractile reserve refers to the difference between myocardial contractility at
rest and during stress either through physiological or pharmacological means. The assessment of
contractile reserve provides an indication of cardiac reserve, which is the maximum amount that
cardiac output can increase from during a state of rest to during a state of stress. Assessment of
the presence of contractile reserve relies on the assessment of change in systolic function or left
ventricular.88 Contractile reserve is measured as the difference in left ventricular function at rest
and under stress. Exercise and inotropic stress have been used as stress protocols for the
assessment of contractile reserve. Both stresses provoke a generalized increase of regional wall
motion as an increment of ejection fraction.89
Myocardial contractile reserve is associated with prognostic biomarkers and molecular
expression in cardiomyocytes. Left ventricular inotropic reserve is associated with exercise
capacity and correlates with peak oxygen consumption (peak VO2) in cardiopulmonary exercise
testing.90–92 Patients with a greater increase in myocardial contractile reserve achieve a greater
peak VO2.92 Impaired left ventricular contractile reserve has been shown to be associated with
cardiac sympathetic dysfunction.93 Reduced adrenergic myocardial contractile reserve is related
to myocardial expression of contractile regulatory protein genes, such as β1 adrenergic receptor,
sarcoplasmic reticulum calcium-adrenergic triphosphatase, and phospholamban.94
Patients with markedly reduced contractility at rest, but a healthy residual contractile
reserve, have a favorable exercise capacity, while patients with mildly reduced contractility at
rest, but significantly reduced contractile reserve, have poor exercise capacity.95 Studies have
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indicated that evaluating the myocardial contractile reserve in pharmacological stress testing and
peak VO2 in cardiopulmonary exercise testing may be complementary approaches to predict a
prognosis of non-ischemic dilated cardiomyopathy. Furthermore, impaired contractile reserve by
pharmacological stress testing may be associated with molecular remodeling caused by
overactivation of the SNS.96
The use of stress echocardiography to assess contractile reserve has shown promise as a
prognostic indicator in the assessment of systolic HF.97 There are reported indications that the
presence of residual contractile reserve is associated with a good prognosis and impaired
contractile reserve is affected by multiple factors including, but not limited to, exercise
intolerance, cardiac sympathetic dysfunction, reduced myocardial blood flow and
histopathological changes. Additionally, there is a suggestion that myocardial contractile reserve
would predict a reversibility of left ventricular dysfunction after initiation of cardioprotective
therapy.96 Previous studies have shown that repeated administrations of IL-1β induces reversible,
acute and chronic, contractile dysfunction and impaired β1 adrenergic responsiveness. (Fig. 5)

Figure 5: Effects of recombinant IL-1β on left ventricular function in the mouse and contractile reserve signaling in HF. IL-1βtreated mice showed impaired contractile reserve with a right shift of the dose–response curve to isoproterenol at 4 hours (acute)
and 15 days (chronic).75
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Goal of the Study
The central hypothesis of the study was that IL-1β diminishes the exercise capacity in the
mouse. The first aim of the study was to determine whether IL-1β decreases exercise tolerance in
the mouse. The second aim of the study was to determine whether changes in the systolic
function and contractile reserve correlate with changes in exercise tolerance.
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Methods and Materials
Ethical Approval
All experimental procedures were conducted in accordance with the “Guide for the Care
and Use of Laboratory Animals” published by the National Institutes of Health (8th ed. revised
2011). The study protocol was approved by the Institutional Animal Care and Use Committee
(IACUC) of Virginia Commonwealth University.

Study Design
This study tested changes that occur to exercise tolerance, left ventricular ejection
fraction, and contractile reserve, 4 hours and 96 hours after administration of IL-1β to mice. The
4-hour time point was chosen because it has been previously reported that IL-1β induces a
significant reduction in LVEF 4 hours after administration, with no changes seen in vehicletreated mice at 4 hours. (Fig. 6)

LVEF (% of baseline)

120
Vehicle

100
P<0.001

80

IL-1b

60

P<0.001

40
20

1

4
24
hours after challenge

Figure 6: IL-1β-induced left ventricular systolic dysfunction in mice. Mice either treated with IL-1β 3 μg/kg or vehicle. LVEF
assessed at multiple time points as a percentage of the baseline (hour 0) LVEF from hour 0 to hour 24.

The 96-hour time point was chosen to provide confidence of normalization of LVEF. In a
previous study, mice were injected with increasing doses of IL-1β, which 4 hours after
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administration, produced significant reductions in LVFS at all doses ≥ 0.3 µg/kg. IL-1β 3 µg/kg
was characterized as a standard dose in subsequent experiments as this dose was the minimum
required to significantly impair contractile function and appeared to give the greatest numerical
reduction in LVEF.84

Figure 7: Healthy, adult, mice underwent baseline echocardiography followed by a single intraperitoneal injection of
recombinant human IL-1β (0, 0.03, 0.3, 3, or 30 µg/kg) and subsequent echocardiography at 4 hours. All doses of IL-1β ≥0.3

µg/kg produced a significant 28 – 32% reduction in left ventricular fractional shortening (LVFS) at 4 hours.84

In this study 52 male Institute of Cancer research (ICR) mice, 8-10 weeks old and
weighing 35-45g, supplied by Envigo (Indianapolis, IN), underwent exercise training and testing.
Based on their baseline exercise capacity, 17 mice were chosen and treated with either IL-1β
(n=10) or a vehicle (n=7). The mice were then tested again 4 hours and 96 hours after
administration to assess the change in their exercise tolerance. A separate group of 25 mice were
assessed for their baseline LVEF via transthoracic echocardiography (TTE). Of these, 13 were
treated with IL-1β and 12 were treated with a vehicle, and their LVEF was assessed 4 hours and
96 hours after administration. The IL-1β-treated mice that did not experience a reduction in
LVEF 4 hours after administration were eliminated from the study. The remaining mice
underwent an isoproterenol challenge to test the heart’s contractile reserve.
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Exercise Testing Protocol
Clinical manifestations of HF include shortness of breath including exercise-induced
dyspnea, exercise intolerance, and fatigue. These symptoms are prominent in numerous other
diseases such as diabetes, which also plays a role in perpetuating HF. A preclinical assay of
fatigue and exercise capacity for rodents is the treadmill.98 Fatigue testing via the rodent
treadmill was a useful testing method in this study where a significant change was seen
following administration of IL-1β.
The exercise training and testing protocol used in this study was adapted from Dougherty
et al., J Vis, 2016.98 The treadmill used was the Exer 3/6 animal treadmill from Columbus
Instruments. It has the capability of exercising up to three rats or six mice, simultaneously, in
individual lanes (5.7 x 41.3 cm for mice, 11.8 x 41.3 cm for rats). The belt speed can be adjusted
from 0.0 to 102.3 m/min, and the running surface can be inclined from 0° to 25° above
horizontal in 5° increments. A stimulus can be created using the electrical shock grid system
composed of six shock grids, each with an individual on/off switch. The intensity and repetition
rate of the stimulus is user controlled (current 0.34 – 1.60 mA, duration 200 msec, repetition rate
1, 2 or 3 Hz). For this study, the treadmill was fixed at a 20° incline and configured to allow six
mice to run at a given time. The shock grid was fixed at 1.22 mA and 2 Hz.
Treadmill exercise testing was used to measure fatigue/exercise intolerance as an effect
of administration of IL-1β. Animals were forced to run to exhaustion on a conveyor belt with
gradually increasing speeds. The animals were motivated to run until they were unable or
unwilling to continue running as a means of escaping electrical shocks. Testing ended when the
animals reached exhaustion, which was defined as at least 5 seconds in the fatigue zone. The
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fatigue zone was defined as the region of the conveyor belt that is within approximately 1 body
length of the shock grid and includes the shock grid itself.
Mice were properly acclimated to the treadmill prior to any experimentation. The
training consisted of three days of subsequently increasing speeds. On day 1, the mice were
placed directly on the treadmill belt in each lane, with the speed at 0 m/min and the shock grids
on. The mice were allowed to explore the treadmill for 5 minutes. The treadmill was turned on
and the speed was slowly increased to 8 m/min. All the mice were monitored to ensure they were
walking against the direction of the belt. If a mouse did not begin walking or was walking toward
the shock grid, they were readjusted by tapping them with a brush or by tail tickling. If a mouse
refused to walk it was excluded from the study. The mice ran for 5 minutes, then the speed was
increased to 9 m/min for 7 minutes, and finally to 10 m/min for 10 minutes. On day 2 of training,
the mice were placed on the belt and the treadmill was turned on at a speed of 10 m/min. After 5
minutes, the speed was increased to 11 m/min for 10 minutes, and finally to 12 m/min for 15
minutes. On day 3 of training, the mice were placed on the belt and the treadmill was turned on
at a speed of 12 m/min. After 5 minutes, the speed was increased to 13 m/min for 10 minutes,
and finally to 14 m/min for 15 minutes. At the end of each session, the shock grid was turned off
and the mice were allowed to rest for 2 minutes before being removed from their lanes. The mice
were rested for 1 day and then underwent a preliminary exercise test to establish their baseline
capacity.
Before starting the treadmill test, the treadmill was set to a speed of 5 m/min. Mice were
individually placed in each lane and the corresponding shock grid was turned on. The mice ran at
a speed of 5 m/min for 5 minutes. The speed was then increased to 14 m/min and the speed was
increased by 2 m/min at 3 minute intervals. The mice were forced to run until they reached a
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state of exhaustion at which point their individual shock grid was turned off, allowing them to
rest. When all the mice reached exhaustion, the treadmill was turned off and they were allowed
to rest for 2 minutes before being removed. A stopwatch was used to monitor the amount of time
each mouse ran. The speed and time were used to determine the distance each mouse ran, which
was representative of their exercise capacity.
Treatment and Testing
The mice were rested for 2 days following the baseline test before they were injected
intraperitoneally. The recombinant IL-1β was administered at a dose of 3 μg/kg in 200 μL, while
the 0.9% normal saline was administered in the same volume. Exercise capacity was assessed as
a measure of distance run on a treadmill at baseline, and 4 hours and 96 hours after injection.

Transthoracic Echocardiography
Transthoracic echocardiography (TTE) was performed to assess the changes in LV
systolic function in IL-1β-treated mice compared to vehicle-treated mice. TTE is a noninvasive
imaging technique that uses ultrasound technology to allow visualization of the heart in real-time
and is an important diagnostic tool for a variety of cardiac pathologies. The high-frequency
sound waves are produced by a piezoelectric crystal contained in a transducer.99 The transducer
emits and then detects ultrasound waves that are reflected from the tissue. These waves are
converted into electrical signals and converted to images based on the density of the tissue.
The echocardiography system used in the study was the Prospect T1 Scintica
Instrumentation Inc. with a transducer probe with a high transmit frequency of 30 MHz. Before
the TTE was performed, each mouse was sedated with ketamine/xylazine (100/10 mg/kg), and
their upper and lower chest was shaved. The mice were then placed and secured in a supine
position on a warmed platform. The TTE operator applied warm ultrasound transmission gel to
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the animal’s chest and then placed the transducer probe on the thoracic region to visualize the
heart from the parasternal short-axis view.
For this study, the animal’s hearts were visualized using B-mode and M-mode in the
echocardiography system. When the transducer was placed in view of the parasternal short-axis,
the B-mode produced images of the heart that allowed visualization of ventricular wall motion
and ventricular size. Using these images, the probe was placed to allow visualization of the left
ventricular wall and, using the M-mode, the left ventricular end-diastolic diameter (LVEDD) and
left ventricular end-systolic diameter (LVESD) were measured. These left ventricular structural
parameters were utilized to calculate LVEF.
LVEF is a measure of the contractile function of the heart and was calculated using the
Teichholz formula. The measured LVEDD and LVESD were converted to volumes using the
following formulas:
LVEDV = (7*LVEDD3)/(2.4+LVEDD)
LVESV = (7*LVESD3)/(2.4+LVESD)
Using the values for left ventricular end-diastolic volume (LVEDV) and left ventricular
end-systolic volume (LVESV), the LVEF was calculated with the following formula:
LVEF = (LVEDV – LVESV)/LVEDV*100
The LVEF was assessed at baseline to ensure that the mice met the inclusion criteria. The
acceptable LVEF for inclusion was >58% at baseline. The selected mice were randomized into
two groups: IL-1β-treated and vehicle-treated groups. The LVEF was assessed again 4 hours and
96 hours after intraperitoneal administration of 200 μL IL-1β 3 μg/kg for the IL-1β-treated group
or 200 μL 0.9% normal saline for the vehicle-treated group. The echocardiography operator was
blinded to the treatments.
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Isoproterenol Challenge and Calculation of the Contractile Reserve
Immediately following the 4-hour and 96-hour echocardiogram, isoproterenol (10 ng)
was injected intraperitoneally to each sedated mouse while in the supine position on the
platform. The isoproterenol dose was chosen from a dose-response study in which 10 ng/mouse
was the highest dose possible before there was a saturated response as seen in Figure 7.
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Figure 8: IL-1β induces β-adrenergic desensitization in the mouse as demonstrated by rightward curve shift during the
isoproterenol challenge. Absolute and relative changes in LVEF are shown with increasing doses of isoproterenol: a right-ward
shift of the dose-response curve reflects desensitization (N=8 per group).

Additional mice were used to measure the contractile reserve in the absence of treatment and
were used as reference controls (N=6/group). The purpose of the challenge was to assess
myocardial contractile reserve. Isoproterenol is a potent, synthetic, β-adrenergic receptor agonist
that has positive chronotropic and inotropic properties through β-adrenergic stimulation. The
effect of IL-1β on systolic function, contractile reserve, and β-adrenergic sympathetic responses
was characterized using the isoproterenol challenge. Using TTE, the LVEF was measured 3-5
minutes after administration of isoproterenol, and the percent increase in LVEF was assessed.
The difference from rest in these parameters, expressed as percentage change, indicates the

22

cardiac reserve. The cardiac reserve was calculated using the following formula: ((LVEF during
stress - LVEF at rest)/ LVEF at rest) * 100 = Cardiac Reserve

Statistical Analysis
All data presented utilized values derived from the procedures explained above.
Additionally, the values from these procedures are presented as the mean, standard error of the
mean, and absolute values. For the exercise tolerance data, a One-way ANOVA was used to
compare changes over time for the vehicle and IL-1β groups. An unpaired T-test was used for
comparison between the vehicle and IL-1β groups at each time point. For the echocardiography
data, a paired T-test was used for comparison from baseline to each time point for both the
vehicle and IL-1β groups. For the contractile reserve data, an unpaired T-test was used for all
comparisons. Unadjusted p-values are reported throughout, with the statistical significance set at
a 2-tailed distribution and a significance level of 0.05 and 0.01.

23

Results
Effects of IL-1β on Exercise Tolerance
There were three rounds of exercise training and testing culminating in the use of 52 mice
total. After each round of exercise training and baseline testing, mice were chosen for the study
based on the distance they ran, which represented their exercise capacity. The mice that ran less
than 220 meters and more than 280 meters were excluded. This represented the lowest third and
highest third of performers. To ensure the vehicle and IL-1β groups had similar averages, the
middle performing group was ordered from least to greatest and every other mouse was assigned
to one group while the rest were assigned to the other. Ultimately, there were 7 vehicle-treated
mice and 10 IL-1β-treated mice.

Figure 9: Absolute values of distance run at each time point. Left panel shows the values for the vehicle-treated group and right
panel shows the values for the IL-1β-treated mice at before, 4 hours, and 96 hours after administration.

The baseline averages for the vehicle-treated and IL-1β-treated groups in the exercise
capacity test were 246 meters and 247 meters, respectively. Administration of IL-1β significantly
reduced exercise capacity after 4 hours, by 32%, and after 96 hours, by 33%, compared to
baseline capacity. The P value for the comparison from each of the time points to baseline for the
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IL-1β-treated group was less than 0.05. There was no significant effect observed in the vehicletreated group after 4 hours or after 96 hours. The exercise capacity for the vehicle-treated group
was significantly greater than the capacity of the IL-1β-treated group at both time points. The P
value comparing the vehicle-treated and IL-1β-treated groups at each time point was less than
0.05.

Vehicle

Figure 10: Averages of distance run by both control and experimental groups during exercise testing before, 4 hours, and 96
hours after administration of a vehicle or IL-1β treatment (*P<0.05 vs Pre; #P<0.05 vs Vehicle).

Effects of IL-1β on Systolic Function
The resting LVEF was used as an evaluation of systolic function in the mice. The
baseline averages for the vehicle-treated and IL-1β-treated groups were 61% and 59%,
respectively. Resting LVEF was measured before, 4 hours, and 96 hours after administration of
vehicle or IL-1β. The LVEF for the IL-1β-treated group was significantly reduced 4 hours after
administration. After 4 hours, there was a 29% reduction with a P value less than 0.01 compared
to the baseline LVEF. After 96 hours, LVEF had recovered to the pre-treatment values seen at
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baseline. The vehicle-treated group showed no significant change in LVEF after administration
of the vehicle at each of the time points. The average LVEF at 96 hours for the vehicle-treated
and the IL-1β-treated groups were 62% and 59%, respectively.

Figure 11: Average resting LVEF for mice before, 4 hours, and 96 hours after administration of a vehicle or IL-1β treatment
(*P<0.01 vs Pre)

Effects of IL-1β on Cardiac Reserve
Cardiac reserve was demonstrated as the change in LVEF after treatment with
isoproterenol, a β-adrenergic stimulator. It was calculated as the percent change from rest to
stress of the LVEF. The change in LVEF at baseline for the vehicle-treated and IL-1β-treated
group were 23% and 26% increase, respectively. There was a diminished cardiac reserve for the
IL-1β-treated group 4 hours after administration of IL-1β. The increase in LVEF was 7% after 4
hours and 2% after 96 hours. The change in LVEF was significantly reduced at both time points
with a P value of 0.01 compared to baseline. The change in LVEF in the vehicle-treated group
was not significantly different at the either of the time points. The P value for the comparison
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between the IL-1β-treated and the vehicle-treated group was less than 0.05 at the 4-hour time
point and less than 0.01 at the 96-hour time point.

Figure 12: Cardiac reserve represented as LVEF change from rest to after β-adrenergic stimulation (*P<0.01 vs Pre; #P<0.05
vs Vehicle; †P<0.01 vs Vehicle)
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Discussion
Improving functional capacity, clinical outcomes, and quality of life in patients with HF
remains an unmet clinical need. Inflammation promotes and aggravates HF.100,101 The effects of
inflammatory cytokines such as IL-1β in HF are a continuous topic of research. The results of the
present study indicate that exogenous IL-1β significantly reduces exercise capacity in mice 4
hours and 96 hours after administration. These results are significant as they are independent of
the changes in LVEF caused by administration of IL-1β. LVEF is only impacted 4 hours after
IL-1β and normalizes by 96 hours.
There are several reports that show that exercise training and exhaustive exertion increase
levels of several cytokines, but there is little knowledge on the effects of select cytokines on the
exercise performance. IL-6 is known to increase during exercise, and it increases exercise
tolerance.102 A single injection of IL-1β significantly increases the IL-6 levels within 4 hours.103
However, in our study, the treatment with recombinant IL-1β produced a reduction in exercise
tolerance within 4 hours and, therefore, suggests that the effects of IL-1β and IL-6 on exercise
capacity are different. Cavalli et al. demonstrated that in mice, a low dose of lipopolysaccharide
(LPS, 10 mg/mouse), a compound from the outer-membrane of Gram-negative bacteria that
binds to the TLR-4, reduced their treadmill run time.104 The administration of IL-37, a cytokine
of the IL-1 family that has anti-inflammatory activity, prevented this decrease. Our dose of IL-1β
was much smaller compared to the LPS, and despite this, it potently reduced the exercise time of
our mice. The IL-1R1 and TLR-4 have similar downstream pathway and it is possible that they
similarly impair the exercise tolerance of mice. However, a dose of LPS lower than 60
mg/mouse (equivalent to 2 mg/kg) is insufficient to induce a reduction in LVEF.105,106 Therefore,
we can hypothesize that in the model used by Cavalli and colleagues, the LVEF was likely
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unaffected by the LPS treatment. We found that exercise intolerance was not dependent on the
LVEF because the LVEF normalized after 96 hours, while the exercise tolerance of the mice was
still impaired. Therefore, the resting LVEF does not correlate with the exercise capacity of the
mice. However, the cardiac reserve was significantly impaired after 4 and 96 hours compared to
the vehicle-treated mice. This suggests that the administration of IL-1β reduces exercise capacity
through an impairment in cardiac reserve. The reduction in exercise capacity and cardiac reserve
after 96 hours indicates a prolonged effect from IL-1β that was previously not reported without
repetitive administration of IL-1β. A study by Van Tassell et al., conducted at Virginia
Commonwealth University, has shown that targeting IL-1 using a recombinant human IL-1
receptor antagonist in patients with HF increases the exercise tolerance of the patients.107 Thus,
our study confirms a direct role of IL-1β as a negative regulator of exercise tolerance.
This present study had several potential drawbacks and limitations. Some of the more
common limitations seen in preclinical studies relate to the use of murine models and the lack of
diverse subjects. Limitations included using only one breed, one sex, using only relatively young
healthy male mice, and having a small sample size. As discussed above, cytokines of the IL-1
family are elevated and contribute to several cardiovascular diseases, including atherosclerosis,
atherothrombosis, and AMI in obesity, and diabetes, hypertension, and dilated
cardiomyopathy.108–110 In those conditions, IL-1β is not the only cytokine that is elevated, and
the levels of several dozens of cytokines are altered. However, our goal was to prove that in
healthy mice, a single dose of IL-1β could show a physiological effect in the absence of
confounding factors. For future studies, performing experiments in mice of different breeds or
performing IL-1β blockade in murine models of HF could be a way to limit these drawbacks.

29

Limitations more unique to this present study are related to the exercise testing protocol
that was used as a preclinical assay of fatigue and exercise capacity.98 The protocol for testing is
subjective and can lead to inter-user error, which can lead to imprecise results. However, a single
user was responsible for the conduction of all the experiments, therefore minimizing variability.
Lastly, we did not identify a molecular mechanism regulating the effects of IL-1β on the
contractile reserve and exercise tolerance. Several pathways that control the contractility and
relaxation of cardiomyocytes have been identified. These include an intracellular increase in
nitric oxide that can be associated with a reduction of ATP production and with the alteration of
cytoplasmatic calcium influx by affecting the coupling of the calcium channel with the βadrenergic receptor.111–114 As discussed above, IL-1 also regulates calcium reuptake in the SR
through downregulation of mRNA and protein levels of phospholamban and SERCA.112,115 A
separate report describes the role of IL-1 in ischemia-induced systolic dysfunction. 116 More
recently, a role for phosphoinositide-3-kinase-γ (PI3Kg) in IL-1 signaling has been identified as
being potentially linked to impaired contractility, phosphodiesterase-3 activity, and β-adrenergic
receptor desensitization.117–121
An unconventional signaling of the IL-1 receptor through PI3Kg has been characterized
in inflammation and cancer.118 PI3Kg expression and activity have been increased in patients
with HF and animal models of HF, negatively regulating cardiac contractility and inhibiting the
physiologic response to β-adrenergic stimulation.121,122 PI3K is a family of kinases that generate
PIP3, which is a key second messenger involved in downstream signaling of its receptors.123 The
main catalytic protein for the PI3Kg isoform, p110g, has adaptor proteins p87 and p101 that
regulate the specificity of its function.121,124,125 Future studies will be performed to define how
IL-1β affects the myocardial expression of PI3Kg and its adaptor proteins looking at gene and
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protein expression, as well at the potential use of PI3Kg inhibitors to prevent the decrease in
exercise tolerance due to IL-1β challenge.
In conclusion, the results presented in this study show that administration of exogenous
IL-1β significantly reduces exercise capacity through an impairment in cardiac reserve, while
being independent of the LVEF at rest.
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